131.16 USD
-1.59 (-1.2%)
131.16 USD
0 (0%)
Taking everything into account, ILMN scores 5 out of 10 in our fundamental rating. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. ILMN has an excellent profitability rating, but there are some minor concerns on its financial health. ILMN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
ILMN had a positive operating cash flow in the past year.
In multiple years ILMN reported negative net income over the last 5 years.
ILMN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ILMN (11.38%) is better than 91.23% of its industry peers.
Looking at the Return On Equity, with a value of 29.53%, ILMN belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 16.40%, ILMN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ILMN (16.39%) is better than 89.47% of its industry peers.
ILMN's Operating Margin of 20.41% is amongst the best of the industry. ILMN outperforms 85.96% of its industry peers.
In the last couple of years the Operating Margin of ILMN has declined.
ILMN has a Gross Margin of 66.74%. This is amongst the best in the industry. ILMN outperforms 87.72% of its industry peers.
ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ILMN is still creating some value.
Compared to 1 year ago, ILMN has about the same amount of shares outstanding.
Compared to 5 years ago, ILMN has more shares outstanding
The debt/assets ratio for ILMN is higher compared to a year ago.
2.2 Solvency
ILMN has an Altman-Z score of 4.37. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
ILMN has a Altman-Z score of 4.37. This is in the better half of the industry: ILMN outperforms 78.95% of its industry peers.
The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.99, ILMN belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio (0.42) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.37 |
ROIC/WACC1.54
WACC10.66%
2.3 Liquidity
A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN's Current ratio of 1.43 is on the low side compared to the rest of the industry. ILMN is outperformed by 78.95% of its industry peers.
ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.12, ILMN is doing worse than 70.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
ILMN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.93% yearly.
Looking at the last year, ILMN shows a decrease in Revenue. The Revenue has decreased by -2.32% in the last year.
Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
The Earnings Per Share is expected to grow by 24.49% on average over the next years. This is a very strong growth
Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 3.93% on average per year.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.49%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.93%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.08, the valuation of ILMN can be described as expensive.
Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than 70.18% of the companies in the same industry.
When comparing the Price/Earnings ratio of ILMN to the average of the S&P500 Index (26.51), we can say ILMN is valued inline with the index average.
With a Price/Forward Earnings ratio of 25.59, ILMN can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than 77.19% of the companies in the same industry.
ILMN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.08 | ||
| Fwd PE | 25.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 78.95% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaply inside the industry as 87.72% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.04 | ||
| EV/EBITDA | 18.06 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ILMN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
131.16
-1.59 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.82%
Inst Owner Change1.59%
Ins Owners0.18%
Ins Owner Change-0.42%
Market Cap20.04B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts72.86
Price Target126.28 (-3.72%)
Short Float %4.86%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)4.82%
PT rev (3m)10.24%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)1.32%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.08 | ||
| Fwd PE | 25.59 | ||
| P/S | 4.67 | ||
| P/FCF | 20.04 | ||
| P/OCF | 17.86 | ||
| P/B | 8.42 | ||
| P/tB | 19.21 | ||
| EV/EBITDA | 18.06 |
EPS(TTM)4.36
EY3.32%
EPS(NY)5.13
Fwd EY3.91%
FCF(TTM)6.54
FCFY4.99%
OCF(TTM)7.34
OCFY5.6%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.31
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.37 |
F-Score7
WACC10.66%
ROIC/WACC1.54
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.49%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.93%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.